Healthcare / Medical - PharmaceuticalsUpdated 2026-05-10 22:07 UTC

LON/0RNK stock hub

LON/0RNK has a live ticker hub with the latest available market, valuation, profitability, growth, ownership, and risk indicators.

Browse stocks

LON/0RNKis not in this month’s coverageGet our monthly research letter — no spam

Fair value midpoint

n/a

Fair value pending

Upside to midpoint

n/a

Based on latest report

Confidence

n/a

Data quality and model convergence

Market cap

816.3M

London Stock Exchange

Market data

Live price

Current market quote for this ticker.

Current price

LON/0RNK

In the news

Latest news · LON/0RNK

Recent company headlines from major financial publishers.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

—

Fetching the latest headlines.

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector context

Where the current metrics sit

Percentiles come from the backend screener cohort cache for the ticker's country and sector.

Forward P/En/a

P25 12.9P50 16.9P75 23.5

Trailing P/En/a

P25 15.9P50 22.9P75 35.8

ROEn/a

P25 -54.2P50 2.1P75 13.7

ROIC-60

P25 -38.1P50 3.3P75 11.9

Benchmarks - 1M

S&P 500n/a

Nasdaq Compositen/a

Dow Jones Industrial Averagen/a

Russell 2000n/a

Indicator catalog

All LON/0RNK market and fundamental indicators

A searchable catalog of the available market, valuation, profitability, growth, balance-sheet, ownership, and analyst metrics for this ticker.

Available fields

167

Groups with data

Currency

EUR

Showing 167 of 167 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Country	France
Country code	UK
Employees	73
Employees Change	-41%
Employees Change Percent	-34.75
Enterprise value	EUR 929.5M
Exchange	London Stock Exchange
Financial currency	EUR
First seen	2026-05-10
Industry	Medical - Pharmaceuticals
Isin	FR0013233012
Last refreshed	2026-05-10
Market cap	EUR 816.3M
Price	EUR 4.49
Price currency	EUR
Rev Per Employee	80,796.07x
Sector	Healthcare
Sic	2836
Symbol	lon/0RNK
Website	https://inventivapharma.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings Yield	-37.84%
EV Earnings	-3.01x
EV/FCF	-10.14x
EV/Sales	159.17x
FCF yield	-11.23%
P/B ratio	-32.81x
P/S ratio	138.41x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
Gross margin	99.67%
Gross Profit	EUR 5.9M
Gross Profit Growth	-58.28%
Gross Profit Growth Q	-90.1%
Gross Profit Growth3 Y	-27.72%
Gross Profit Growth5 Y	-20.42%
Net Income	EUR -308.9M
Net Income Growth Years	0%
Pretax Margin	-5,237.63%
Profit Per Employee	EUR -4.2M
ROA	-45.08
Roa5y	-46.67
ROCE	-77.2
ROIC	-59.97

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
Cagr1y	39.56%
Cagr3y	24%
Cagr5y	-17.79%
EPS Growth Quarters	1
EPS Growth Years	1
Revenue Growth	-52.03x
Revenue Growth Q	-89.87x
Revenue Growth Years	0x
Revenue Growth3 Y	-29.05x
Revenue Growth5 Y	-21.05x

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Asset Turnover	EUR 0.04
Assets	EUR 217.7M
Cash	EUR 87.1M
Current Assets	EUR 211.5M
Current Liabilities	EUR 66.9M
Debt	EUR 201.4M
Debt FCF	EUR -2.2
Equity	EUR -24.9M
Interest Coverage	-3.96
Liabilities	EUR 242.5M
Long Term Assets	EUR 6.2M
Long Term Liabilities	EUR 175.6M
Net Cash	EUR -114.3M
Net Cash By Market Cap	EUR -14
Tangible Book Value	EUR -25M
Tangible Book Value Per Share	EUR -0.13
WACC	9.58

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Current ratio	3.16
Net Working Capital	EUR 86.9M
Quick ratio	1.41
Working Capital	EUR 145.8M
Working Capital Turnover	EUR 0.07

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback Yield	-212.49%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
1Y total return	39.53%
200-day SMA	4.34
3Y total return	90.71%
50-day SMA	4.89
50-day SMA vs 200-day SMA	50over200
5Y total return	-62.45%
All Time High	14.9
All Time High Change	-69.85%
All Time High Date	2021-02-09
All Time Low	1.46
All Time Low Change	208.15%
All Time Low Date	2024-10-08
ATR	0.22
Beta	0.88
Ch YTD	14.67
High	4.57
High52	6.19
High52 Date	2026-01-23
High52ch	-27.42%
Low	4.47
Low52	2.6
Low52 Date	2025-06-27
Low52ch	72.8%
Ma50ch	-8.16%
Price vs 200-day SMA	3.47%
RSI	46.6
RSI Monthly	54.16
RSI Weekly	49.21
Sharpe ratio	0.81x
Sortino ratio	1.38
Total Return	-212.49%
Tr YTD	14.69
Tr1m	-5.17%
Tr1w	2.23%
Tr3m	-7.76%

Analyst estimates

Ratings, targets, revisions, and forward estimate fields.

Metric	Value
Operating Income	EUR -115.9M
Operating margin	-1,965.5

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	122,208,545%
Net Borrowing	-5,172,889.5
Shares Insiders	4.76%
Shares Institutions	51.27%
Shares Qo Q	143.26%
Shares Yo Y	212.49%

Other indicators

Additional ticker metrics that do not fit the primary research groupings yet.

Metric	Value
Adjusted FCF	EUR -115.1M
Average Volume	7,068x
Bv Per Share	-0.13
CAPEX	EUR -215,476
Ch1m	-5.17
Ch1w	2.23
Ch1y	39.53
Ch3m	-7.76
Ch3y	90.7
Ch5y	-62.45
Ch6m	26.74
Change	-3.52%
Change From Open	-0.16
Close	4.66
Days Gap	-3.36
Depreciation Amortization	335,632.3
Dollar Volume	49,277.1
Earnings Date	2026-09-25
EBIT	EUR -115.9M
EBITDA	EUR -115.6M
EPS	EUR -1.65
F Score	3
FCF	EUR -91.7M
FCF EV Yield	-9.87x
Financing CF	210,491,368
Fiscal Year End	December
Founded	2,011
Income Tax	EUR 19,192
Investing CF	-116,187,857
Is Primary Listing	0
Last Earnings Date	2026-03-30
Last Report Date	2025-12-31
Ma150	4.44
Ma150ch	1.12%
Ma20	4.51
Ma20ch	-0.31%
Net CF	2,397,281
Next Earnings Date	2026-09-25
Open	4.5
Position In Range	24.01
Ppne	2,576,929.4
Price Date	2026-05-08
Relative Volume	1.55x
Revenue	5,898,113x
SBC By Revenue	395.93x
Share Based Comp	23,352,550
Tax By Revenue	0.33x
Tr6m	26.74%
Volume	10,968
Z Score	-1.98

Fast facts

Decision checkpoints

A compact product layer over the same report payload.

Risk gate

n/a

Named kill scenarios are reviewed before any bullish rating can stand.

Moat score

n/a

Business quality stays separate from stock attractiveness.

Forward P/E

n/a

Valuation uses the full report model stack, not a single multiple.

Next action

Research pending

Final action steps are kept in the recommendation tab.

Income

Does LON/0RNK pay a dividend?

Capital-return profile for this ticker.

Performance

LON/0RNK stock returns vs the market

Total return (incl. dividends) compared to S&P 500.

Ownership

Who owns LON/0RNK?

Insider, institutional, and short-interest positioning.

Institutional ownership

+51.3%

Share of float held by funds and institutions

Insider ownership

+4.8%

Stake held by company insiders. Higher generally signals alignment.

Short interest

n/a

Float sold short by bearish positioning

Y/Y dilution

+212.5%

Negative means the company is buying back shares.

Technical

LON/0RNK momentum and risk profile

RSI, moving-average stack, beta, and risk-adjusted return.

RSI (14)

46.6

Neutral momentum band

Price vs 200-day MA

+3.5%

50/200-day relationship not available

Beta (5Y)

0.88

Moves roughly with the market

Sharpe ratio

0.81

Risk-adjusted return — higher is better; >1.0 is solid.

Questions

About LON/0RNK

Hub-level FAQ points readers to the deeper analysis pages.

What is the current lon/0RNK stock rating?

lon/0RNK is currently shown with the latest rating in the latest report. The hub links directly to the full analysis surface where the rating, fair-value bridge, risks, and scorecard are documented together.

Where can I read the full lon/0RNK analysis?

The full report lives at /stocks/lon/0RNK/analysis. The bare ticker page is a product hub that summarizes the latest read and sends readers into the relocated analysis tabs without making the analysis surface depend on the hub.

What fair-value range is used for lon/0RNK?

The latest report frames lon/0RNK around the latest fair-value range. Treat that range as the entry point, then check the valuation, sensitivity, and bear-case tabs before making an investment decision.

How often is the lon/0RNK page updated?

The hub updates with the latest published stock report and live backend market data. The analysis pages remain reachable under /analysis, so a hub rollback does not remove the report reader.